Cirrhotic cardiomyopathy is defined as a chronic cardiac dysfunction in patients with cirrhosis. It is suspected that this specific cardiac dysfunction contributes to the onset of complications in liver disease. The purpose of this prospective, randomized controlled trial is to determine whether carvedilol can revert cardiac dysfunction i.e. left ventricular diastolic dysfunction secondary to cirrhosis, and prevent complications (renal dysfunction, worsening cardiac function, and mortality).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
189
Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure\> 90 mmHg.
Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure\> 90 mmHg. If carvedilol is not tolerated,Ivabradine is added in a dose starting 2.5 mg BD to a maximum of 15 mg/day to ensure targeted heart rate reduction
Institute of Liver & Biliary Sciences
New Delhi, National Capital Territory of Delhi, India
Progression of cirrhosis and its complications.
Time frame: 1 Year
Improvement in left ventricular diastolic function in either arm.
Time frame: 1 Year
Renal function
Renal function is being checked- urea, creatinine, urine sediment, and creatinine clearance as calculated by Cockcroft - Gault formula
Time frame: 1 Year
Serum level of Brain Natriuretic Peptide.
Time frame: 1 Year
Mortality
Time frame: 1 Year
Quality of life
Time frame: 1 Year
Electrophysiologic modifications
Electrophysiological changes checked are QTc interval, documentation of arrhythmias
Time frame: 1 Year
Serum level of catecholamines
Time frame: 1 year
Serum level of plasma renin activity
Time frame: 1 Year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.